Trials / Unknown
UnknownNCT06068569
Study of the Vector Vaccine GamCovidVac for the Prevention of COVID-19 With Altered Antigenic Profile With Participation of Adult Volunteers
Safety, Reactogenicity and Immunogenicity Study of the Vector Vaccine GamCovidVac for the Prevention of Coronavirus (COVID-19) Infection Caused by the SARS-CoV-2 Virus With Altered Antigenic Profile With Participation of Adult Volunteers
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Safety, reactogenicity and immunogenicity study of the vector vaccine GamCovidVac for the prevention of coronavirus (COVID-19) infection caused by the SARS-CoV-2 virus with altered antigenic profile with participation of adult volunteers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile) | Two intramuscular injections of the GamCovidVac vector vaccine for the prevention of COVID-19 (with altered antigenic profile) will be performed. 1st injection - component I, 2nd injection - component II. |
Timeline
- Start date
- 2023-10-01
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
- First posted
- 2023-10-05
- Last updated
- 2023-10-05
Source: ClinicalTrials.gov record NCT06068569. Inclusion in this directory is not an endorsement.